233 related articles for article (PubMed ID: 17258882)
21. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
[TBL] [Abstract][Full Text] [Related]
22. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
[TBL] [Abstract][Full Text] [Related]
23. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.
Lai Q; Inostroza M; Rico Juri JM; Goffette P; Lerut J
HPB (Oxford); 2015 Dec; 17(12):1085-95. PubMed ID: 26373980
[TBL] [Abstract][Full Text] [Related]
24. Alpha-fetoprotein and
Yang Z; Luo FZ; Wang S; Lerut J; Zhuang L; Li QY; Xu X; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):229-234. PubMed ID: 32303439
[TBL] [Abstract][Full Text] [Related]
25. Peri-Transplant Change in AFP Level: a Useful Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation.
Yoo T; Lee KW; Yi NJ; Choi YR; Kim H; Suh SW; Jeong JH; Lee JM; Suh KS
J Korean Med Sci; 2016 Jul; 31(7):1049-54. PubMed ID: 27366001
[TBL] [Abstract][Full Text] [Related]
26. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.
Peng SY; Chen WJ; Lai PL; Jeng YM; Sheu JC; Hsu HC
Int J Cancer; 2004 Oct; 112(1):44-50. PubMed ID: 15305374
[TBL] [Abstract][Full Text] [Related]
27. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma.
Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Kim IH; Yi NJ; Lee KU
Surgery; 2007 May; 141(5):598-609. PubMed ID: 17462459
[TBL] [Abstract][Full Text] [Related]
28. [Impact of serum α-fetoprotein level on short-term recurrence after R0 resection in primary hepatocellular carcinoma].
Li SP; Wu LQ
Zhonghua Wai Ke Za Zhi; 2013 Jul; 51(7):600-3. PubMed ID: 24256584
[TBL] [Abstract][Full Text] [Related]
29. Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma.
de Ataide EC; Garcia M; Mattosinho TJ; Almeida JR; Escanhoela CA; Boin IF
Transplant Proc; 2012 Oct; 44(8):2438-40. PubMed ID: 23026614
[TBL] [Abstract][Full Text] [Related]
30. Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality.
Mahmud N; John B; Taddei TH; Goldberg DS
Clin Transplant; 2019 Jul; 33(7):e13634. PubMed ID: 31177570
[TBL] [Abstract][Full Text] [Related]
31. Glutamate dehydrogenase and alkaline phosphatase as very early predictors of hepatocellular carcinoma recurrence after liver transplantation.
Piras-Straub K; Khairzada K; Gerken G; Saner F; Treckmann J; Paul A; Canbay A; Herzer K
Digestion; 2015; 91(2):117-27. PubMed ID: 25662469
[TBL] [Abstract][Full Text] [Related]
32. Relevance of Pre-Transplant α-fetoprotein Dynamics in Liver Transplantation for Hepatocellular Cancer.
Grąt M; Krasnodębski M; Patkowski W; Wronka KM; Masior Ł; Stypułkowski J; Grąt K; Krawczyk M
Ann Transplant; 2016 Feb; 21():115-24. PubMed ID: 26887339
[TBL] [Abstract][Full Text] [Related]
33. Prediction of hepatocellular carcinoma recurrence after liver transplantation: Comparison of four explant-based prognostic models.
Costentin CE; Amaddeo G; Decaens T; Boudjema K; Bachellier P; Muscari F; Salamé E; Bernard PH; Francoz C; Dharancy S; Vanlemmens C; Radenne S; Dumortier J; Hilleret MN; Chazouillères O; Pageaux GP; Calderaro J; Laurent A; Roudot-Thoraval F; Duvoux C;
Liver Int; 2017 May; 37(5):717-726. PubMed ID: 28199760
[TBL] [Abstract][Full Text] [Related]
34. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.
Shindoh J; Sugawara Y; Nagata R; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Kokudo N
Transpl Int; 2014 Apr; 27(4):391-8. PubMed ID: 24472068
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma.
Harimoto N; Yoshida Y; Kurihara T; Takeishi K; Itoh S; Harada N; Tsujita E; Yamashita YI; Uchiyama H; Soejima Y; Ikegami T; Yoshizumi T; Kawanaka H; Ikeda T; Shirabe K; Saeki H; Oki E; Kimura Y; Maehara Y
Transplant Proc; 2015 Apr; 47(3):703-4. PubMed ID: 25819732
[TBL] [Abstract][Full Text] [Related]
36. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
[TBL] [Abstract][Full Text] [Related]
37. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.
Grąt M; Kornasiewicz O; Lewandowski Z; Hołówko W; Grąt K; Kobryń K; Patkowski W; Zieniewicz K; Krawczyk M
World J Surg; 2014 Oct; 38(10):2698-707. PubMed ID: 24858191
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the risk factors of untransplantable recurrence after primary curative resection for patients with hepatocellular carcinoma.
Ho CM; Wu CY; Lee PH; Lai HS; Ho MC; Wu YM; Hu RH
Ann Surg Oncol; 2013 Aug; 20(8):2526-33. PubMed ID: 23504121
[TBL] [Abstract][Full Text] [Related]
39. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?
Adam R; Azoulay D; Castaing D; Eshkenazy R; Pascal G; Hashizume K; Samuel D; Bismuth H
Ann Surg; 2003 Oct; 238(4):508-18; discussion 518-9. PubMed ID: 14530722
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors for hepatocellular carcinoma recurrence: experience with 83 liver transplantation patients.
Ataide EC; Boin IF; Almeida JR; Sevá-Pereira T; Stucchi RS; Cardoso AR; Caruy CA; Escanhoela CA
Transplant Proc; 2011 May; 43(4):1362-4. PubMed ID: 21620130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
